Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

Stock Information for Clearmind Medicine Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Clearmind Medicine Inc.

Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study
Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity
Revive Therapeutics Advances with Next-Generation Bucillamine Development
Revive Therapeutics Announces Proposed Shares for Debt Transaction
Revive Therapeutics to Investigate Bucillamine's Potential in Cancer Treatment
Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program
Revive Therapeutics Announces Results of Annual Shareholder Meeting
Revive Therapeutics Announces LOI to Acquire DiagnaMed's Molecular Hydrogen Program

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.